valdecoxib has been researched along with lopinavir in 1 studies
Studies (valdecoxib) | Trials (valdecoxib) | Recent Studies (post-2010) (valdecoxib) | Studies (lopinavir) | Trials (lopinavir) | Recent Studies (post-2010) (lopinavir) |
---|---|---|---|---|---|
375 | 71 | 86 | 2,383 | 499 | 1,358 |
Protein | Taxonomy | valdecoxib (IC50) | lopinavir (IC50) |
---|---|---|---|
ATP-dependent translocase ABCB1 | Homo sapiens (human) | 1.7 | |
Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 9.12 | |
Gag-Pol polyprotein | Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE) | 0.035 | |
Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 8.5114 | |
Protease | Human immunodeficiency virus 1 | 0.025 | |
Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 7.6 | |
Protease | Human immunodeficiency virus 1 | 0.0175 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
1 other study(ies) available for valdecoxib and lopinavir
Article | Year |
---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |